Armata (ARMP) Stock Surges 150% After Breakthrough Bacteriophage Trial Results
Armata Pharmaceuticals shares soared 155% to $8.87 on Oct. 22 after reporting positive Phase 2a results for its IV phage therapy against Staph. aureus infections, with 88% cure rates versus 58% for placebo. Trading volume hit 10.6 million shares, far above average. No serious drug-related side effects were reported. Analysts raised price targets to $9 following the news.
